Lutetium Lu 177 Dotatate – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 17 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Lutetium Lu 177 Dotatate is a radio-conjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
New weakness, severe pain, high fever, or symptoms after a serious injury.
Any symptom that feels urgent, unusual, or unsafe for the patient.

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Definition

Lutetium Lu 177 Dotatate is a radio-conjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and at position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.

Lutetium Lu 177–Edotreotide is a radio-conjugate consisting of the somatostatin analog edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radio-conjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 positions of the somatostatin analog octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecane tetraacetic acid (DOTA).

A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatment called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times. In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated lower whole-body retention, indicating a potentially lower risk for bone marrow toxicity. The presence of a radioligand allows monitoring of treatment response post-therapy and prior to the next fraction of the dose delivery which may be clinically beneficial in estimating the intensity of ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।" data-rx-term="lesion" data-rx-definition="A lesion is an abnormal area of tissue such as a spot, wound, patch, lump, or ulcer. সহজ বাংলা: শরীরের অস্বাভাবিক দাগ, ক্ষত বা ফোলা অংশ।">lesion uptakes or deciding the dose for subsequent administrations. Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. It is the first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs. Targeting the pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine tumors may commonly metastasize to the mesentery, peritoneum, and liver. Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared to patients receiving octreotide alone and there was evidence of an overall survival benefit.

Mechanism of Action

Somatostatin receptors (SSRT) are inhibitory G-protein coupled receptors that are ubiquitously expressed in normal and cancer cells. The natural ligand of SSRTs, somatostatin, is a potent inhibitory regulator of pituitary and gastrointestinal hormone release and proliferation. Advanced and well-differentiated neuroendocrine tumors express high levels of somatostatin receptors, especially somatostatin receptor type 2 (SSRT2), and have the ability to incorporate amines intracellularly and decarboxylate them. As an analog of somatostatin, Lutetium Lu 177 dotatate binds to somatostatin receptors with the highest binding affinity for SSRT2. Upon binding to SSRT-expressing cells, including malignant somatostatin receptor-positive tumors, the radiolabelled compound is internalized and the beta emission from the radioligand Lu 177 induces cellular damage by the formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. As with other somatostatin analogs, Lu177 dotatate is expected to suppress the excessive secretion of amines and hormones, such as serotonin, from carcinoid tumors and certain types of endocrine pancreatic tumors (glucagonoma, VIPoma, and gastrinoma). The release of peptides and other gastrointestinal hormones important in tumor growth, including gastrin, cholecystokinin, and epidermal growth factor (EGF), may also be reduced through promoted somatostatin signaling pathways.

Clinically significant myelosuppression occurred in less than 10% of patients in the Lutetium Lu 177 dotatate (177Lu-Dotatate) group in one clinical trial. According to an open-label study involving 20 patients with somatostatin receptor-positive midgut carcinoid tumors, the treatment with did not result in any large changes in the mean QTc interval (i.e., >20 ms). Due to high expression of SSTR2, pancreas was the primary target in animal studies using a non-radioactive form of lutetium Lu 177 dotatate (lutetium Lu 175 dotatate).

Indications

Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) in adults.
Gastroenteropancreatic Neuroendocrine Tumors
It is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.^[rx]
Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Use in Cancer

Lutetium Lu 177-dotatate is approved to treat:

Gastroenteropancreatic neuroendocrine tumors. It is used in adults whose cancer is somatostatin receptor positive.

Lutetium Lu 177-dotatate is also being studied in the treatment of other types of cancer.

Contraindications

low amount of albumin proteins in the blood
anemia
decreased blood platelets
low levels of a type of white blood cell called neutrophils
high amount of jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin in the blood
pregnancy
a patient who is producing milk and breastfeeding
chronic kidney disease stage 1 with mild signs of kidney damage
chronic kidney disease stage 2 (mild)
chronic kidney disease stage 3A (moderate)
chronic kidney disease stage 3B (moderate)
chronic kidney disease stage 4 (severe)
chronic kidney disease stage 5 (failure)
kidney disease with likely reduction in kidney function

Dosage

Strengths: 370 MBq/mL

Neuroendocrine Carcinoma

Intravenous infusion: 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses.
Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) for at least 4 weeks prior to initiating this drug. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating this drug.
During treatment: Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each dose of this drug. Do not administer long-acting octreotide within 4 weeks of each subsequent dose. Short-acting octreotide may be given for symptomatic management during treatment with this drug, but must be withheld for at least 24 hours before each dose of this drug.
Following treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing this drug until disease progression or for up to 18 months following treatment initiation.

Antiemetic

Administer antiemetics 30 minutes before the recommended amino acid solution.

Amino Acid Solution:

Initiate an intravenous amino acid solution containing L-lysine and L-arginine 30 minutes before administering this drug.
Use a three-way valve to administer amino acids using the same venous access as this drug or administer amino acids through a separate venous access in the patient’s other arm.
Continue the infusion during, and for at least 3 hours after infusion of this drug.
Do not decrease the dose of the amino acid solution if the dose of this drug is reduced.
Dose modifications due to adverse reactions are provided in the dose adjustment section.
Radiation Dosimetry: The maximum penetration in tissue is 2.2 mm and the mean penetration is 0.67 mm.

Renal Dose Adjustments

Mild to moderate renal dysfunction:

No adjustment is recommended.
Patients may be at greater risk of toxicity; frequent assessments of renal function should be performed.

Severe renal dysfunction (CrCl less than 30 mL/min) and ESRD: Safety has not been studied.

If creatinine clearance is less than 40 mL/min, 40% increase, or 40% decrease in baseline serum creatinine:

Withhold dose until complete or partial resolution.
Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution.
If the reduced dose does not result in renal toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose.
Permanently discontinue this drug for renal toxicity requiring a treatment delay of 16 weeks or longer.
Recurrent renal toxicity: Permanently discontinue this drug.

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment is recommended.
Severe liver dysfunction (total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin 3 times more the upper limit of normal and any AST): Safety has not been studied.

If bilirubinemia is greater than 3 times the upper limit of normal (Grades 3 or 4) or hypoalbuminemia is less than 30 g/L with a decreased prothrombin ratio of less than 70%:

Withhold the dose until complete or partial resolution.
Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution.
If the reduced dose does not result in hepatotoxicity, administer this drug at 7.4 GBq (200 mCi) for next dose.
Permanently discontinue this drug for hepatotoxicity requiring a treatment delay of 16 weeks or longer.
Recurrent hepatotoxicity: Permanently discontinue this drug.

Dose Adjustments

platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">Thrombocytopenia Grade 2, 3 or 4:

Withhold dose until complete or partial resolution (Grade 0 to 1)
Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution.
If the reduced dose does not result in Grade 2, 3 or 4 platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose.
Permanently discontinue this drug for Grade 2 or higher toxicity requiring a treatment delay of 16 weeks or longer.
Recurrent toxicity Grade 2, 3 or 4: Permanently discontinue this drug.

Anemia and bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">Neutropenia Grade 3 or 4; Other Non-Hematologic Toxicity Grade 3 or 4:

Withhold dose until complete or partial resolution: Anemia and neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">Neutropenia (0, 1, or 2); Other Non-Hematologic Toxicity (0 to 2)
Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution.
If the reduced dose does not result in Grade 3 or 4 toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose.
Permanently discontinue this drug for Grade 3 or higher toxicity requiring a treatment delay of 16 weeks or longer.
Recurrent Grade 3 or 4: Permanently discontinue this drug.

Administration advice:

Handle appropriate safety measures to minimize radiation exposure.
Use an aseptic technique, waterproof gloves, tongs, and radiation shielding when administering this drug.
This drug should be used by or under the control of physicians qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
Do not administer as an intravenous bolus.
During the infusion, ensure that the level of solution in the vial remains constant.
The manufacturer’s product information should be consulted.

Reconstitution/preparation techniques:

Do not inject directly into any other intravenous solution.
Confirm the amount of radioactivity of this drug in the radiopharmaceutical vial with an appropriate dose calibrator prior to and after administration.
Inspect the product visually for particulate matter and discoloration prior to administration under a shielded screen. Discard vial if particulates or discoloration are present.
Dispose of any unused medicinal product or waste material in accordance with local and federal laws.
The manufacturer’s product information should be consulted.

Patient advice:

Patients should contact their healthcare provider for any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, or increased bleeding or bruising.
There is a potential for secondary cancers, including myelodysplastic syndrome and acute leukemia.
Patients should hydrate and urinate frequently during and after the administration of this drug.
Periodic laboratory tests to monitor for hepatotoxicity is recommended.
Patients should contact their healthcare provider for signs or symptoms that may occur following tumor-hormone release, including severe flushing, diarrhea, bronchospasm, and hypotension.

Side Effects

The Most Common

dry mouth or throat
nausea
vomiting
diarrhea
constipation
stomach pain
decreased appetite
decreased weight
change in the ability to taste
headache
dry eye
unusual tiredness or weakness, pale skin, dizziness, shortness of breath
unusual bleeding or bruising
fever, chills, sore throat, or other signs of infection
mouth sores
increased or decreased urination
swelling of the arms, hands, feet, ankles, or lower legs

More common

Agitation
anxiety
black, tarry stools
bleeding gums
blood in the urine or stools
blurred vision
chills
cold sweats
confusion
cool, pale skin
cough
decreased urine output
diarrhea
difficulty in breathing
dizziness
dry mouth
feeling of warmth
fever
flushed, dry skin
fruit-like breath odor
headache
hoarseness
hostility
increased hunger
increased thirst
increased urination
irritability
joint pain, stiffness, or swelling
loss of appetite
loss of consciousness
lower back, side, arm, leg, or stomach pain
mood changes
mood or mental changes
muscle cramps in the hands, arms, feet, legs, or face
muscle pain or twitching
nausea
nervousness
nightmares
numbness and tingling around the mouth, lips, hands, fingertips, or feet
painful or difficult urination
pale skin
pinpoint red spots on the skin
pounding in the ears
rapid weight gain
redness of the face, neck, arms, and occasionally, upper chest
restlessness
seizures
shakiness
slow, fast, or irregular heartbeat
slurred speech
sore throat
sweating
swelling of the face, feet, lower legs, ankles, or hands
tremor
troubled breathing
troubled breathing with exertion
ulcers, sores, or white spots in the mouth
unexplained weight loss
unusual bleeding or bruising
unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
vomiting
weakness or heaviness of the legs

Rare

Bone pain
chest pain or discomfort
dilated neck veins
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
extreme tiredness or weakness
irregular breathing
pain or discomfort in the arms, jaw, back, or neck
swollen glands
Constipation
decreased appetite
hair loss or thinning of the hair
loss or change in taste
Difficulty in moving
neck pain

Drug Interactions

DRUG	INTERACTION
Lanreotide	The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide.
Octreotide	The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.
Pasireotide	The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Pasireotide.
Somatostatin	The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Somatostatin.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)]. There are no available data on PLUVICTO use in pregnant females. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm

Lactation

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during lutetium Lu 177 dotatate therapy and for 2.5 months following the last dose, which would usually mean permanently discontinuing breastfeeding of the current infant.

Why is this medication prescribed?

Lutetium Lu 177 vipivotide tetraxetan injection is used to treat a certain type of prostate cancer (cancer of a male reproductive gland) that has spread to other parts of the body and that has already been treated with other medications. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to cancer cells which damages and kills these cells.

How should this medicine be used?

Lutetium Lu 177 vipivotide tetraxetan comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually injected slowly over 1 to 10 minutes or it may be infused slowly over up to 30 minutes. It may be given once every 6 weeks for up to 6 doses depending on how well your body responds to the medication and the side effects that you experience.

Your doctor will probably tell you to drink plenty of water before you receive lutetium Lu 177 vipivotide tetraxetan injection and to urinate as often as possible during the first hours after you receive a dose.

Your doctor may reduce your dose or temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with lutetium Lu 177 vipivotide tetraxetan. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving lutetium Lu 177 vipivotide tetraxetan injection,

tell your doctor and pharmacist if you are allergic to lutetium Lu 177 vipivotide tetraxetan, any other medications, or any of the ingredients in lutetium Lu 177 vipivotide tetraxetan injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
tell your doctor if you often get any type of infection or if you think you may have any type of infection now. Also tell your doctor if have previously received radiation therapy or if you have or have ever had cancer; bleeding problems; anemia (a lower than normal number of red blood cells); abnormal blood levels of sodium, potassium, or calcium; or liver or kidney problems.
you should know that lutetium Lu 177 vipivotide tetraxetan injection is for use only in men. If your female partner is not pregnant but could become pregnant, you and your partner must use birth control during your treatment and for 14 week after your final dose. If your partner becomes pregnant while you are receiving this medication, call your doctor. Lutetium Lu 177 vipivotide tetraxetan may harm the fetus.
you should know that this medication may temporarily or permanently cause infertility in men. However, you should not assume that your female partner cannot become pregnant during your treatment.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving lutetium Lu 177 vipivotide tetraxetan injection.
you should minimize exposing other people to radiation after you receive a dose of lutetium Lu 177 vipivotide tetraxetan by limiting close contact with other people. Stay at least 3 feet away from household contacts for 2 days and from children and pregnant women for 7 days. You should also sleep in a separate bedroom apart from household contacts for 3 days, apart from children for 7 days, and apart from pregnant women for 15 days. You should also avoid sexual activity for 7 days after receiving a dose of lutetium Lu 177 vipivotide tetraxetan injection.

What special dietary instructions should I follow?

Make sure you drink plenty of water or other fluids while you are receiving lutetium Lu 177 vipivotide tetraxetan injection.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Website

Name or nickname Phone / contact District / area Age group Sex Severity today

Main symptoms How long has it been happening? Medicines already taken Tests already done Your question 0/1200

Frequently Asked Questions

Mechanism of Action Somatostatin receptors (SSRT) are inhibitory G-protein coupled receptors that are ubiquitously expressed in normal and cancer cells. The natural ligand of SSRTs, somatostatin, is a potent inhibitory regulator of pituitary and gastrointestinal hormone release and proliferation. Advanced and well-differentiated neuroendocrine tumors express high levels of somatostatin receptors, especially somatostatin receptor type 2 (SSRT2), and have the ability to incorporate amines intracellularly and decarboxylate them. As an analog of somatostatin, Lutetium Lu 177 dotatate binds to somatostatin receptors with the highest binding affinity for SSRT2. Upon binding to SSRT-expressing cells, including malignant somatostatin receptor-positive tumors, the radiolabelled compound is internalized and the beta emission from the radioligand Lu 177 induces cellular damage by the formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. As with other somatostatin analogs, Lu177 dotatate is expected to suppress the excessive secretion of amines and hormones, such as serotonin, from carcinoid tumors and certain types of endocrine pancreatic tumors (glucagonoma, VIPoma, and gastrinoma). The release of peptides and other gastrointestinal hormones important in tumor growth, including gastrin, cholecystokinin, and epidermal growth factor (EGF), may also be reduced through promoted somatostatin signaling pathways. Clinically significant myelosuppression occurred in less than 10% of patients in the Lutetium Lu 177 dotatate (177Lu-Dotatate) group in one clinical trial. According to an open-label study involving 20 patients with somatostatin receptor-positive midgut carcinoid tumors, the treatment with did not result in any large changes in the mean QTc interval (i.e., >20 ms). Due to high expression of SSTR2, pancreas was the primary target in animal studies using a non-radioactive form of lutetium Lu 177 dotatate (lutetium Lu 175 dotatate). Indications Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) in adults. Gastroenteropancreatic Neuroendocrine Tumors It is a chelated complex of a radioisotope of the element lutetium with DOTA-TATE, used in peptide receptor radionuclide therapy (PRRT). Specifically, it is used in the treatment of cancers which express somatostatin receptors.[rx] Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Use in Cancer Lutetium Lu 177-dotatate is approved to treat: Gastroenteropancreatic neuroendocrine tumors. It is used in adults whose cancer is somatostatin receptor positive. Lutetium Lu 177-dotatate is also being studied in the treatment of other types of cancer. Contraindications low amount of albumin proteins in the blood anemia decreased blood platelets low levels of a type of white blood cell called neutrophils high amount of bilirubin in the blood pregnancy a patient who is producing milk and breastfeeding chronic kidney disease stage 1 with mild signs of kidney damage chronic kidney disease stage 2 (mild) chronic kidney disease stage 3A (moderate) chronic kidney disease stage 3B (moderate) chronic kidney disease stage 4 (severe) chronic kidney disease stage 5 (failure) kidney disease with likely reduction in kidney function Dosage Strengths: 370 MBq/mL Neuroendocrine Carcinoma Intravenous infusion: 7.4 GBq (200 mCi) every 8 weeks for a total of 4 doses. Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) for at least 4 weeks prior to initiating this drug. Administer short-acting octreotide as needed; discontinue at least 24 hours prior to initiating this drug. During treatment: Administer long-acting octreotide 30 mg intramuscularly 4 to 24 hours after each dose of this drug. Do not administer long-acting octreotide within 4 weeks of each subsequent dose. Short-acting octreotide may be given for symptomatic management during treatment with this drug, but must be withheld for at least 24 hours before each dose of this drug. Following treatment: Continue long-acting octreotide 30 mg intramuscularly every 4 weeks after completing this drug until disease progression or for up to 18 months following treatment initiation. Antiemetic Administer antiemetics 30 minutes before the recommended amino acid solution. Amino Acid Solution: Initiate an intravenous amino acid solution containing L-lysine and L-arginine 30 minutes before administering this drug. Use a three-way valve to administer amino acids using the same venous access as this drug or administer amino acids through a separate venous access in the patient's other arm. Continue the infusion during, and for at least 3 hours after infusion of this drug. Do not decrease the dose of the amino acid solution if the dose of this drug is reduced. Dose modifications due to adverse reactions are provided in the dose adjustment section. Radiation Dosimetry: The maximum penetration in tissue is 2.2 mm and the mean penetration is 0.67 mm. Renal Dose Adjustments Mild to moderate renal dysfunction: No adjustment is recommended. Patients may be at greater risk of toxicity; frequent assessments of renal function should be performed. Severe renal dysfunction (CrCl less than 30 mL/min) and ESRD: Safety has not been studied. If creatinine clearance is less than 40 mL/min, 40% increase, or 40% decrease in baseline serum creatinine: Withhold dose until complete or partial resolution. Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution. If the reduced dose does not result in renal toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue this drug for renal toxicity requiring a treatment delay of 16 weeks or longer. Recurrent renal toxicity: Permanently discontinue this drug. Liver Dose Adjustments Mild to moderate liver dysfunction: No adjustment is recommended. Severe liver dysfunction (total bilirubin 3 times more the upper limit of normal and any AST): Safety has not been studied. If bilirubinemia is greater than 3 times the upper limit of normal (Grades 3 or 4) or hypoalbuminemia is less than 30 g/L with a decreased prothrombin ratio of less than 70%: Withhold the dose until complete or partial resolution. Resume this drug at 3.7 GBq (100 mCi) in patients with complete resolution. If the reduced dose does not result in hepatotoxicity, administer this drug at 7.4 GBq (200 mCi) for next dose. Permanently discontinue this drug for hepatotoxicity requiring a treatment delay of 16 weeks or longer. Recurrent hepatotoxicity: Permanently discontinue this drug. Dose Adjustments Thrombocytopenia Grade 2, 3 or 4: Withhold dose until complete or partial resolution (Grade 0 to 1) Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If the reduced dose does not result in Grade 2, 3 or 4 thrombocytopenia toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue this drug for Grade 2 or higher toxicity requiring a treatment delay of 16 weeks or longer. Recurrent toxicity Grade 2, 3 or 4: Permanently discontinue this drug. Anemia and Neutropenia Grade 3 or 4; Other Non-Hematologic Toxicity Grade 3 or 4: Withhold dose until complete or partial resolution: Anemia and Neutropenia (0, 1, or 2); Other Non-Hematologic Toxicity (0 to 2) Resume this drug at 3.7 GBq (100 mCi) in patients with complete or partial resolution. If the reduced dose does not result in Grade 3 or 4 toxicity, administer this drug at 7.4 GBq (200 mCi) for the next dose. Permanently discontinue this drug for Grade 3 or higher toxicity requiring a treatment delay of 16 weeks or longer. Recurrent Grade 3 or 4: Permanently discontinue this drug. Administration advice: Handle appropriate safety measures to minimize radiation exposure. Use an aseptic technique, waterproof gloves, tongs, and radiation shielding when administering this drug. This drug should be used by or under the control of physicians qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals. Do not administer as an intravenous bolus. During the infusion, ensure that the level of solution in the vial remains constant. The manufacturer's product information should be consulted. Reconstitution/preparation techniques: Do not inject directly into any other intravenous solution. Confirm the amount of radioactivity of this drug in the radiopharmaceutical vial with an appropriate dose calibrator prior to and after administration. Inspect the product visually for particulate matter and discoloration prior to administration under a shielded screen. Discard vial if particulates or discoloration are present. Dispose of any unused medicinal product or waste material in accordance with local and federal laws. The manufacturer's product information should be consulted. Patient advice: Patients should contact their healthcare provider for any signs or symptoms of myelosuppression or infection, such as fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. There is a potential for secondary cancers, including myelodysplastic syndrome and acute leukemia. Patients should hydrate and urinate frequently during and after the administration of this drug. Periodic laboratory tests to monitor for hepatotoxicity is recommended. Patients should contact their healthcare provider for signs or symptoms that may occur following tumor-hormone release, including severe flushing, diarrhea, bronchospasm, and hypotension. Side Effects The Most Common dry mouth or throat nausea vomiting diarrhea constipation stomach pain decreased appetite decreased weight change in the ability to taste headache dry eye unusual tiredness or weakness, pale skin, dizziness, shortness of breath unusual bleeding or bruising fever, chills, sore throat, or other signs of infection mouth sores increased or decreased urination swelling of the arms, hands, feet, ankles, or lower legs More common Agitation anxiety black, tarry stools bleeding gums blood in the urine or stools blurred vision chills cold sweats confusion cool, pale skin cough decreased urine output diarrhea difficulty in breathing dizziness dry mouth feeling of warmth fever flushed, dry skin fruit-like breath odor headache hoarseness hostility increased hunger increased thirst increased urination irritability joint pain, stiffness, or swelling loss of appetite loss of consciousness lower back, side, arm, leg, or stomach pain mood changes mood or mental changes muscle cramps in the hands, arms, feet, legs, or face muscle pain or twitching nausea nervousness nightmares numbness and tingling around the mouth, lips, hands, fingertips, or feet painful or difficult urination pale skin pinpoint red spots on the skin pounding in the ears rapid weight gain redness of the face, neck, arms, and occasionally, upper chest restlessness seizures shakiness slow, fast, or irregular heartbeat slurred speech sore throat sweating swelling of the face, feet, lower legs, ankles, or hands tremor troubled breathing troubled breathing with exertion ulcers, sores, or white spots in the mouth unexplained weight loss unusual bleeding or bruising unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness vomiting weakness or heaviness of the legs Rare Bone pain chest pain or discomfort dilated neck veins dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position extreme tiredness or weakness irregular breathing pain or discomfort in the arms, jaw, back, or neck swollen glands Constipation decreased appetite hair loss or thinning of the hair loss or change in taste Difficulty in moving neck pain Drug Interactions DRUG INTERACTION Lanreotide The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Lanreotide. Octreotide The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide. Pasireotide The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Pasireotide. Somatostatin The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Somatostatin. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy The safety and efficacy of PLUVICTO have not been established in females. Based on its mechanism of action, PLUVICTO can cause fetal harm [see Clinical Pharmacology (12.1)]. There are no available data on PLUVICTO use in pregnant females. No animal studies using lutetium Lu 177 vipivotide tetraxetan have been conducted to evaluate its effect on female reproduction and embryo-fetal development; however, all radiopharmaceuticals, including PLUVICTO, have the potential to cause fetal harm Lactation Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. No information is available on the use of lutetium Lu 177 dotatate during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during lutetium Lu 177 dotatate therapy and for 2.5 months following the last dose, which would usually mean permanently discontinuing breastfeeding of the current infant. Why is this medication prescribed?

How should this medicine be used?

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

Read, save, and share this guide

Understand this article easily